NCT07468123
Atrial Fibrillation Risk Estimation With Single-lead Handheld Electrocardiograms
Enrolling by Invitation
NAAges 18–90InterventionalDiagnosticMassachusetts General HospitalInvestigator-initiated
~200 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:1L ECG screeningPatch monitor
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
New AF diagnosis (%)
Measured over 1 year
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Men and women aged 50-90 who are new or established patients in an MGH primary care or ambulatory cardiology practice
Willing to provide consent to participate in the study to access data from electronic health records (EHR)
At least 1 12-lead ECG obtained within 5 years prior to study start date for AF risk estimation
Have access to a smart phone or tablet to use with the AliveCor KardiaMobile 1L ECG device
Exclusion
History of atrial fibrillation or atrial flutter as documented in the patient's current electronic health record medical problem list or self-reported diagnosis
Implanted cardiac devices (pacemakers, implantable cardiac defibrillators, or cardiac resynchronization therapy, and implantable loop recorders)
History of allergy to adhesive
What this trial measures
- New AF diagnosis (%)1 year
Rate of new AF diagnosis
- Acceptability and usefulness0
Survey-based acceptability and usefulness of 1L ECG screening process
- AI-based AF risk correlation0
Correlation between 12-lead ECG-based AF risk and 1L ECG-based AF risk using AI model